Brian Bergmark
Latest contributions
LDL-C management: should it begin in the cathlab?
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session examines the evolving role of LDL cholesterol management in patients undergoing percutaneous coronary intervention (PCI), with a focus on the potential benefits of initiating intensive lipid-lowering strategies early in the patient pathway.
The discussion reviews emerging evidence on PCSK9 inhibition in elective PCI...
Long-term mortality following PCI with DES vs. CABG for left main disease
21 May 2026 – From EuroPCR 2026
This major late-breaking trial from EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting stents (DES) versus CABG for left main coronary artery disease. Combining long-term data from the EXCEL, NOBLE, PRECOMBAT, and SYNTAX trials, the analysis found remarkably similar mortality outcomes between the...
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...
